Skip to main navigation Skip to search Skip to main content

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Article number183
JournalBlood cancer journal
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this